Richard J. Turner
Career history of Richard J. Turner
Former positions of Richard J. Turner
| Companies | Position | Start | End |
|---|---|---|---|
Transcriptogen Ltd.
 Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Director/Board Member | - | 2017-06-16 |
| Chief Executive Officer | - | 2017-06-16 | |
Catalyst Venture Partners Ltd.
 Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Chief Executive Officer | 2011-04-28 | - |
| Founder | 2011-04-28 | - | |
| Private Equity Investor | 1998-12-31 | 2010-08-31 | |
| Corporate Officer/Principal | 1998-12-31 | 2011-04-28 |
Statistics
International
| United Kingdom | 3 |
Operational
| Chief Executive Officer | 2 |
| Founder | 1 |
| Private Equity Investor | 1 |
Sectoral
| Finance | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Catalyst Venture Partners Ltd.
Catalyst Venture Partners Ltd. Investment ManagersFinance Catalyst Venture Partners Ltd. (CVP) is a London-based independent corporate finance advisory and private equity partnership established in 1999 by a group of technology entrepreneurs. Catalyst Venture Partners Ltd. | Finance |
Transcriptogen Ltd.
Transcriptogen Ltd. BiotechnologyHealth Technology Transcriptogen Ltd. operates as a drug discovery company to exploit the use of small molecules to inhibit the interaction of transcription factors (TFs) with their cognate DNA-recognition site, thus down-regulating or inhibiting the transcription of disease-related genes. The firm develops and discovers anti-cancer drugs. The company was founded by Khondaker Miraz Rahman, Paul Jackson, and Sheraz Gul and is headquartered in Bath, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Richard J. Turner
- Experience
